ALTERITY THERAPEUTICS LTD (ATHE) Stock Analysis
ALTERITY THERAPEUTICS LTD
▾ What's in the 41/100 risk score? (higher = riskier)
Contributions (weight × component score) sum to the total. This near-term score now includes fundamental health (leverage, FCF trend). See the Financial Health section for the full balance-sheet read.
How to read ATHE (pre-profit growth)
This company is reinvesting instead of generating profit, so a standard DCF cannot price it. The useful question is whether the growth the market is paying for is achievable — and whether the company can fund itself until then.
-
1
Reverse-DCF — the growth the price demands ↓
It shows exactly how fast the business must grow to justify today's price. Compare that to what comparable companies have actually achieved.
-
2
Cash runway ↓
Can it reach profitability before it has to raise money and dilute shareholders?
-
3
Interactive calculator ↓
Set your own growth + margin assumptions and see what the business would be worth if you are right.
It files little or nothing with the SEC — so our cash-flow models, financial statements, and U.S. insider data (Form 4) don't apply. What's still real: the live U.S. price and short positioning. Here's what we could pull from other sources:
📑 Read the real filings: latest SEC 6-K ↗
Identity, share count and tier from FINRA + OTC Markets; not a substitute for the home-market financial statements. Thin U.S. disclosure + OTC trading is itself a risk factor.
How does ATHE stack up against its closest peers?
We take the 4 same-industry companies most similar to ATHE (similar size) and check what investors are paying for each dollar of their revenue (or profits). If ATHE is much more expensive on the same yardstick, that's a red flag — unless you have a specific reason it deserves a premium. For a leveraged business, EV/EBIT and FCF yield (both in the table) are usually more reliable than EV/Sales, because revenue multiples ignore differences in margins and debt.
▾ What's "EV / Sales" in plain English?
EV (Enterprise Value) = market cap + total debt − cash. It's "what you'd pay to buy the entire company outright" — you pay the market cap to shareholders and take over their debt, but you keep their cash. EV is fairer than market cap alone because it includes the debt the new owner inherits.
EV / Sales = EV ÷ annual revenue. So "2.5×" means investors pay $2.50 of enterprise value per $1 of yearly sales. Higher = market is paying more per dollar of sales (usually because they expect future growth or fat margins).
p25 / median / p75 are the 25th, 50th (middle), and 75th percentile of the peers' multiples. Half the peers fall between p25 and p75. The median (p50) is the typical peer — that's the benchmark we compare to.
Bold middle number = median peer. Half the peers trade above it, half below. Computed over 4 same-industry peers; implausible multiples excluded.
⚠️ Important caveat: peer multiples only work if the peers are genuinely comparable. Always check the peer list below — if the auto-picker grabbed micro-caps or unrelated businesses, the comparison is noise. A medical-device giant priced against tiny biotech startups won't produce a useful signal.
▾ View peer list (4)
| Ticker | Company | Industry | Mcap | EV/Sales | EV/GP | EV/EBIT | FCF Yield |
|---|---|---|---|---|---|---|---|
| UTHR | UNITED THERAPEUTICS Corp | Pharmaceuticals | $23.6B | 7.4x | 8.4x | 15.8x | 3.3% |
| ZLAB | Zai Lab Ltd | Pharmaceuticals | $19.6B | 43.0x | — | — | 0.8% |
| SPRO | Spero Therapeutics, Inc. | Pharmaceuticals | $12.4B | 981.8x | — | 1,957.0x | 0.1% |
| RGC | Regencell Bioscience Holdings Ltd | Pharmaceuticals | $11.8B | — | — | — | — |
Quality & solvency checks
Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
The Z-score needs working capital, retained earnings, EBIT, sales and total assets from the latest balance sheet, and at least one of those isn't reported in machine-readable form here — common for foreign private issuers. We leave it blank rather than compute a distress verdict from an estimated input. It doesn't affect the reported figures in the financial tables below.
Why it matters: High score = fundamentals improving. Low score = deteriorating. Especially powerful for filtering cheap stocks: cheap + high F-score historically outperforms; cheap + low F-score is often a value trap.
Reference: 7–9 = strong · 4–6 = mediocre · 0–3 = weak
Full explanation →
The F-score compares two consecutive years of income, cash-flow and balance-sheet data. We have 0 years of income data for this filer, but no machine-readable cash-flow statement or balance sheet — so several of the nine checks have no input at all. We show nothing rather than score a partial year against itself. The reported figures in the financial tables below are unaffected.
A standard discounted cash flowDCF — Discounted Cash Flow — sums up all future cash a business will produce, adjusted for the fact that future dollars are worth less than dollars today.
Why it matters: It is the most fundamentally honest valuation method when applicable — but only works for companies with predictable, positive cash flow.
Reference: Best for: mature, profitable businesses. Fails for: pre-profit growth, banks, REITs.
Full explanation → (DCF) valuation is not meaningful for Alterity Therapeutics Ltd (ATHE) because its free cash flowFree Cash Flow (FCF) — Operating cash flow minus capital spending: cash left after a company covers operating costs, taxes and interest and reinvests in the business — but BEFORE repaying debt principal or paying dividends. The cash actually available to investors.
Why it matters: A company can show big profits on paper while burning through cash. FCF is what actually fills the bank account.
Reference: Healthy mature businesses convert 8–15% of revenue into FCF · Growth companies often negative
Full explanation → is negative, indicating a cash-burning growth stage. The model projects no positive equity value under current assumptions, making valuation highly speculative. Investors are likely betting on the potential success of its drug pipeline, which is not captured by backward-looking cash flow models. The primary quantifiable risk is the company's inability to generate positive free cash flow, as flagged by the model.
As of 3 months ago
Anatomy of a share
What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.
What you actually need to decide
Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.
Why it matters: A company can show big profits on paper while burning through cash. FCF is what actually fills the bank account.
Reference: Healthy mature businesses convert 8–15% of revenue into FCF · Growth companies often negative
Full explanation →, implying that without successful drug development and commercialization, the company will require ongoing dilutive equity financing to sustain operations.
- Results from ongoing Phase 2 clinical trials
- Updates on regulatory submissions and approvals
- Announcements of new strategic partnerships or funding rounds
Management & Leadership
Alterity Therapeutics Ltd is led by CEO Dr. Geoffrey K. Chambers, who has been with the company for several years. The company focuses on developing treatments for neurodegenerative diseases. Dr. Chambers' leadership is central to guiding the company's clinical development programs.
What They Make
Alterity Therapeutics develops therapeutic solutions for neurodegenerative diseases, primarily targeting disorders like Parkinson's disease and Multiple System Atrophy. Its products are aimed at patients suffering from these debilitating conditions.
End Markets
Revenue Drivers
Why Is It Priced Like This?
Why Customers Pay
The income statement and balance sheet are also too incomplete here to substitute another lens honestly, so this page carries price, momentum and disclosure facts only.
The market is pricing ATHE based on expectations for its future drug pipeline, rather than current cash flow, which is negative. The model implies no positive equity value, suggesting investors are assigning value to potential drug catalysts and regulatory approvals, which are not in the model. The company's low franchise/durability score of 0/5 also indicates a speculative investment.
Business Model & Valuation
How They Make Money
The company funds itself primarily through equity raises, as indicated by its negative free cash flowFree Cash Flow (FCF) — Operating cash flow minus capital spending: cash left after a company covers operating costs, taxes and interest and reinvests in the business — but BEFORE repaying debt principal or paying dividends. The cash actually available to investors.
Why it matters: A company can show big profits on paper while burning through cash. FCF is what actually fills the bank account.
Reference: Healthy mature businesses convert 8–15% of revenue into FCF · Growth companies often negative
Full explanation → and cash-burning growth stage.
Growth / Revenue DCF
No cash flow statement data available - using revenue/margin growth model as fallback.
Show advanced inputs
| Revenue Growth | 15.0% |
What this model does NOT do: this is a consolidated owner-earnings FCF model. Standalone segment assumptions: none. It does not project its revenue segments independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.
Maturity & Competitive Position
Moat Signals
Revenue and EPSEPS — Earnings per share — net income divided by shares outstanding.
Why it matters: The basis for the P/E ratio. But "earnings" is an accountant's figure — easier to manipulate than cash flow.
Full explanation → trends are not available from current data sources, but the company is in a cash-burning growth stage.
Geography & Markets
Alterity Therapeutics is headquartered in Australia, with clinical operations and research activities spanning multiple international regions, including the United States and Europe, to support its drug development programs.
Geographic Risks
Market Signals
These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.
Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
Reference: 30–70 normal · >70 overbought · <30 oversold
Full explanation → (14)45.0NeutralMomentum is balanced — neither overbought nor oversold.
Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
Reference: Line above signal = bullish momentum · below = bearish
Full explanation →BearishLine below signalThe fast trend is below the slow trend — short-term momentum is currently downward.
Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.
QUALITY
Data Quality & Risk Flags (3 notes — click to expand/collapse)
Guardrail Notes (3)
- FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.
- INVARIANT: weighted IV is non-positive. Model may not be appropriate.
- Model implies no positive equity value under these assumptions. Valuation is speculative/low-confidence.
FINANCIALS
Financial Statements (5-year tables — click to expand)
From ALTERITY THERAPEUTICS LTD's SEC filings (EDGAR).
Recent video coverage
Top recent YouTube videos by date. We don't endorse the channels — these are surfaced for context.
![Alterity Therapeutics stock analysis - would ChatGPT buy or sell today? [June 2025] thumbnail](https://i.ytimg.com/vi/y-OBAMfIARs/mqdefault.jpg)
![Alterity Therapeutics stock analysis - would ChatGPT buy or sell today? [June 2025] thumbnail](https://i.ytimg.com/vi/SxP-rozxfuU/mqdefault.jpg)
Similar companies worth a look
Same sector and industry, similar fundamentals shape. Verify everything yourself — this list is computed mechanically and does not reflect our judgment about whether any of these are a good investment.